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Trimethylation of histone H3 on Lys36 (H3K36me3) by SETD2 is linked to actively transcribed
regions. Li et al. identify a novel role for H3K36me3 that facilitates DNA mismatch repair (MMR)
in cells by targeting the MMR machinery to chromatin during the cell cycle, thereby explaining
certain cases of MMR-defective cancers.Cells are constantly under attack by
DNA damaging agents of both exogenous
and endogenous origin. These assaults
cause various DNA lesions that are
normally corrected by specially adapted
cellular DNA repair machineries. Loss
or deregulation of DNA repair factors
can therefore foster the accumulation of
DNA errors and genome instability, a hall-
mark of cancer that is also implicated in
aging, immune deficiencies, and neuro-
degenerative disorders (Jackson andBar-
tek, 2009).
One specialized and highly evolution-
arily conserved DNA repair pathway is
DNAmismatch repair (MMR) that corrects
base-base mismatches and insertion/
deletion loops (IDLs) of simple repeated
sequences arising as occasional errors
during DNA replication. These lesions
are recognized by two protein complexes,
belonging to the MutS homolog (MSH)
family, that are crucial for successful
MMR. In human cells, one of these, the
most abundant MMR recognition com-
plex that is termed hMutSa, comprises a
heterodimer of hMSH2 and hMSH6 pro-
teins that binds to base-basemismatches
and small IDLs. Although partially over-
lapping in function with hMutSa, the less
abundant hMSH2/hMSH3 heterodimer
complex (hMutSb) mainly deals with
larger IDLs. Importantly, MMR loss
leads to a specific mutator phenotype
characterized by microsatellite instability
(MSI), a change in the number of
simple sequence repeats that causes
predisposition to various cancers, espe-
cially colorectal cancers (Jiricny, 2006).
Nevertheless, a striking and puzzlingfinding in the MMR field has been that
a significant number of colorectal and
several other MSI-positive cancers do
not display genetic or epigenetic defects
in any known MMR genes. What could
the molecular basis for MSI in these
cancers be?
Although the biochemical properties of
MMR factors on naked DNA substrates
have been well characterized (Jiricny,
2006), previous work has shown that
DNA mismatches in the context of tightly
associated nucleosomes, in contrast to
naked DNA, represent poor MMR sub-
strates in such cell-free systems (Li
et al., 2009) (Figure 1A). In light of this
and because chromatin is becoming
increasingly recognized for its impact on
various DNA repair pathways (Miller and
Jackson, 2012), Li et al. (2013), as re-
ported in this issue of Cell, explored
whether chromatin organization is key to
effective MMR. Specifically, they began
their investigations by focusing on the
observation that the hMSH6 subunit
of hMutSa contains a Pro-Trp-Trp-Pro
(PWWP) domain, a proline and trypto-
phan-rich region that is found in several
chromatin factors, some of which were
recently shown to use their PWWP
domain as a reader for H3K36 methylated
histone marks (reviewed in Wagner and
Carpenter, 2012). Through a series of
biochemical and cellular assays, Li et al.
firmly establish that hMSH6 indeed binds
to tri- and, to a lesser extent, dimethylated
H3K36 marks in vitro in a PWWP-depen-
dent manner and show that this mediates
hMutSa association with chromatin in
cells. These data thereby define what isCellconceivably the first direct connection
between an MMR repair factor and a
histone mark (Figure 1B, left). What then
is the functional significance of these
findings?
H3K36me3 is tightly linked to actively
transcribed genome regions, where it pre-
vents transcription initiation from cryptic
gene promoters in the wake of elongating
RNA polymerase II and can also direct
alternative splicing events (Luco et al.,
2010; Wagner and Carpenter, 2012).
What is much less appreciated is that
this mark is cell-cycle regulated, with it
peaking in late G1/early S—where it likely
concentrates at boundaries of early repli-
cation domains (Ryba et al., 2010)—and
being largely depleted in late S/G2 (Li
et al., 2013). By linking it to MMR, Li
et al. now provide a likely functional rele-
vance for this regulation: because DNA
mismatches usually arise through occa-
sional proofreading errors by DNA poly-
merases during DNA replication, the
enrichment of H3K36me3 during S phase
may facilitate recruitment of the MMR
machinery to where (chromatin) and
when (during DNA replication) it is most
needed. Consistent with this idea, Li
et al. establish that abolishing this mark
by shRNA-mediated depletion of the
corresponding histone methyltransferase
SETD2 (the sole enzyme that can cata-
lyze the transition from H3K36me2 to
H3K36me3 in mammalian cells) (Wagner
and Carpenter, 2012) impaired hMutSa
chromatin binding, led to MSI, and
increased mutation rates in the HPRT
gene in these cells. Even more impressive
is the fact that Li et al. found a renal cell153, April 25, 2013 ª2013 Elsevier Inc. 513
Figure 1. A Novel Role of Chromatin in MMR
(A) Although MMR of naked DNA (top) has been fully reconstituted in vitro, when the DNA substrate
contains tightly associated nucleosomes (cylinders, bottom), MMR is inhibited, suggesting that additional
chromatin factors are needed to repair mismatches in mammalian cells.
(B) Left: Li et al. identify SETD2 and the histone mark it catalyzes, H3K36me3, as MMR regulators. They
find that the hMutSa subunit, hMSH6, binds H3K36me3 via its PWWP domain, especially when
H3K36me3 is enriched in late G1/early S phase. Note that hMSH6a targeting also appears to be poten-
tiated by a PIP box that appears to interact with PCNA associated with the replication complex. Right: Li
et al.’s findings help explain the MSI phenotype of human cancer cell lines with no known defects in
classical MMR factors. Conversely, SETD2 inactivation in human cell lines triggers MSI and increases
mutation rates.
(C) Despite the impact of H3K36me3 on MMR, this mark is not sufficient to allow effective MMR, as
biochemical assays containing native nucleosomes (that will contain H3K36me3) do not reconstitute
MMR, suggesting the need in vivo for additional chromatin regulators and/or the presence of replication
machinery components or the replication process itself.
Mut., mutation; PIP, PCNA interacting protein box; PTMs, posttranslational modifications.carcinoma and a Burkitt’s lymphoma cell
line, both MSI positive but without defects
in known MMR genes, to be mutated in
SETD2, thus leading to impaired hMutSa
recruitment to chromatin in a manner
that could be corrected by restoring
the H3K36me3 mark to these cells.
These data thereby offer a satisfying514 Cell 153, April 25, 2013 ª2013 Elsevier Inexplanation for the long-standing discrep-
ancy between the genotypes and pheno-
types of such cancers (Figure 1B, right).
Collectively, the study of Li et al. paves
the way for a multitude of future investiga-
tions. For instance, because H3K36me3
marks active transcription units, it will be
intriguing to test whether this chromatin-c.induced pathway of hMutSa recruitment
displays parallels with the transcription-
coupled repair branch of nucleotide exci-
sion repair that corrects various DNA
lesions, including UV-induced damage,
in actively transcribed genome regions
(Tornaletti, 2009). Does hMutSa analo-
gously provide a genome safety mecha-
nism primarily dedicated toward active
transcription units, and does hMutSb,
which does not contain a PWWP domain,
mediate more generally distributed MMR
throughout the genome? Employing new
DNA sequencing technologies could
shed light on such spatial preferences
of different MMR pathways by investi-
gating not only the mutation frequencies
arising upon loss of certain MMR factors
but also the distributions of ensuing
mutations in relation to transcription
units, chromatin domains, and/or other
genomic features. Further data mining of
existing MSI-positive cancer genome
data sets for other gene mutations could
also identify additional chromatin marks
and regulators that influenceMMR. These
studies seem particularly worthwhile
because MMR in biochemical assays is
still inhibited by nucleosomes even in the
presence of H3K36me3 (Li et al., 2013),
suggesting the requirement for additional
chromatin regulators and/or replication
machinery components or the replication
process itself for successful MMR to
ensue in vivo (Figure 1C). In this regard,
it will be of interest to assess whether
the PWWP domain of hMSH6 could bind
to additional histone marks and, if so,
how such marks might influence MMR.
Because hMSH6 contains not only a
PWWP domain but also a PCNA-interact-
ing protein (PIP) box (Figure 1B) that
targets hMutSa to the replication fork, it
will be interesting to study how these
two domains function together to pro-
mote optimal chromatin/DNA targeting
of hMutSa. Furthermore, Li et al.’s find-
ings raise the question how exactly
hMutSa is released from H3K36me3
to reach its final destination on nucleo-
some-free replicating DNA. Because
H3K36me3 levels are not only determined
by histone methyltransferases, such as
SETD2, but also by histone demethy-
lases, for instance of the KDM4 family
(Kooistra and Helin, 2012), it seems likely
that a tightly regulated interplay between
the activities of these two protein families
may fine-tune H3K36 methylation during
the cell cycle and may thus also regulate
MMR in vivo. In this regard, it will be inter-
esting to see whether misregulated activ-
ity of KDM4 family proteins is associated
with tumors, particularly those of the
MSI variety. Further studies into relation-
ships between DNA repair pathways and
chromatin regulators therefore seem
poised to not only provide new insights
into DNA repair processes but may also
suggest new opportunities for better diag-
nosing and treating cancer and perhaps
other age-related human diseases.REFERENCES
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